Evidence map›Paper›PMID 42882492›Full record

ReviewCells2026

The SKP2-Substrate Axis in Hematological Malignancies: Mechanisms of Oncogenesis and Opportunities for Targeted Therapy.

Yueying Zhang, Omar Faruq, Mariusz Shrestha, Shamila D Alipoor, Hong Chang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yueying ZhangLaboratory Medicine Program, Department of Laboratory Hematology, University Health Network, Toronto, ON M5G 2C4, Canada.
Omar FaruqLaboratory Medicine Program, Department of Laboratory Hematology, University Health Network, Toronto, ON M5G 2C4, Canada.ORCID 0000-0003-2951-4286
Mariusz ShresthaDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Shamila D AlipoorDepartment of Biomedical and Clinical Sciences, Linköping University, SE-581 83 Linköping, Sweden.ORCID 0000-0002-3855-2682
Hong ChangLaboratory Medicine Program, Department of Laboratory Hematology, University Health Network, Toronto, ON M5G 2C4, Canada.

Funding

Leukemia and lymphoma society of Canada
6 · The paper itself

Abstract

S-phase kinase-associated protein 2 (SKP2), a key substrate-recognition subunit of the Skp1-Cul1-F-box (SCF) E3 ubiquitin ligase complex, promotes the ubiquitin-proteasome-mediated degradation of tumor suppressors such as p27

Indexed as

CarcinogenesisHematologic NeoplasmsMolecular Targeted TherapyS-Phase Kinase-Associated ProteinsAnimalsHumansProteolysis Targeting ChimeraProteolysis Targeting ChimeraSKP2 protein, humanS-Phase Kinase-Associated Proteinshematological malignanciesprognostic markerSCF complexSKP2targeted therapyubiquitination

Identifiers

PMID42882492
PMCPMC13664101

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.